A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma

Cancer Res. 2001 Oct 15;61(20):7375-8.


We have performed association studies between a novel coding single nucleotide polymorphism (D104N) in endostatin, one of the most potent inhibitors of angiogenesis, and prostate cancer. We observed that heterozygous N104 individuals have a 2.5 times increased chance of developing prostate cancer as compared with homozygous D104 subjects (odds ratio, 2.4; 95% confidence interval, 1.4-4.16). Modeling of the endostatin mutant showed that the N104 protein is stable. These results together with the observation that residue 104 is evolutionary conserved lead us to propose that: (a) the DNA segment containing this residue might contain a novel interaction site to a yet unknown receptor; and (b) the presence of N104 impairs the function of endostatin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics*
  • Aged
  • Angiogenesis Inhibitors / chemistry
  • Angiogenesis Inhibitors / genetics*
  • Angiogenesis Inhibitors / physiology
  • Collagen / chemistry
  • Collagen / genetics*
  • Collagen / physiology
  • Endostatins
  • Genetic Predisposition to Disease
  • Humans
  • Male
  • Middle Aged
  • Models, Molecular
  • Peptide Fragments / chemistry
  • Peptide Fragments / genetics*
  • Peptide Fragments / physiology
  • Polymorphism, Genetic*
  • Prostatic Neoplasms / genetics*
  • Static Electricity
  • Surface Properties


  • Angiogenesis Inhibitors
  • Endostatins
  • Peptide Fragments
  • Collagen